MONTREAL – Trading in Valeant Pharmaceutical shares was briefly halted today on the Toronto Stock Exchange as its stock fell 30 per cent in morning trading.
The Quebec-based company saw its shares plummet to $102.78, setting a new 52-week low.
It has been under a considerable degree of political and legal scrutiny in the United States over increases to some drug prices.
Drug maker Valeant expects higher profits despite U.S. pricing probe
Sticker shock: How the prices of life-saving drugs skyrocket overnight
MORE: Meet the Canadian ‘poster boy’ behind skyrocketing drug prices
The company is also facing questions published in an analyst report today about its use of specialty pharmaceutical companies to distribute its products.
Valeant shares have taken a beating since the launch of U.S. investigations into pricing for two heart drugs and its patient assistance program.
A week ago, the company said that U.S. Attorney’s offices in Massachusetts and New York had court orders for it to produce documents.
Officials with Valeant could not immediately be reached for comment.